ResistancePlus® GC

Smarter diagnostics. Simplified patient care.

Detect Neisseria gonorrhoeae and ciprofloxacin susceptibility markers: dual N. gonorrhoeae targets (opa & porA), gyrA S91F mutant, & gyrA S91 wildtype in a single-well multiplex qPCR test

Why use ResistancePlus® GC?

Antibiotic resistance in gonorrhoea infections is a global concern. There are limited effective treatment options and novel antibiotics are not readily available. Smarter and more directed use of antibiotics can be achieved through Resistance Guided Therapy.

• Global surveillance data indicate 50-70% of gonorrhoea infections remain susceptible to ciprofloxacin.

• Guidelines for gonorrhoea management call to preserve ceftriaxone and recommend use of ciprofloxacin when susceptibility information is available.

• Azithromycin resistance is rising, compromising dual-therapy options.

Tested on hundreds of clinical samples, ResistancePlus^® GC demonstrates excellent sensitivity and specificity.

ResistancePlus® GC workflow solution

Streamline your workflow and increase productivity for rapid, routine diagnostics. Full automation options including sample and qPCR set-up, through to validated software solutions for automated result calling and simple data processing.

• Validated on a range of specimen types and collection devices

• Unique triple target solution, ideal for confirming GC positives or for upfront testing with simultaneous resistance status

SpeeDx analysis software included in contract pricing is license free and installed on a high security and GDPR compliant platform:

• audit trails

• user traceability

• LIS connectivity

• QA and batch management

Increase capacity of your existing qPCR instrumentation through universal run conditions compatible with all ResistancePlus^® products.

ResistancePlus® GC Performance Specifications

Demonstrated clinical performance — for more detail please see the ResistancePlus^® GC Instructions for Use